Physician profile
Perry Fishkind
NPI 1306950233
$797.19
in general payments reported to CMS, 2019-2025
12 companies · $272 in 2025
The $272 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.44 · 2020: $27.84 · 2021: $73.30 · 2022: $87.85 · 2023: $139 · 2024: $119 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $171.41 | 2019-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $155.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $150.30 | 2021-2025 | Bexsero, Penmenvy |
| Seqirus USA INC | $58.36 | 2025 | Flucelvax |
| Neos Therapeutics, LP | $58.20 | 2019-2021 | |
| Pfizer INC. | $51.00 | 2024 | |
| Merck Sharp & Dohme LLC | $44.08 | 2022-2024 | Vaxneuvance, Vaxelis, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $36.26 | 2023-2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $21.26 | 2025 | Neffy |
| Meridian Bioscience INC. | $19.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.08 | 2025 | |
| Ironshore Pharmaceuticals INC. | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Fishkind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.